Fundraising Fox
/Companies
Sign in

Galvanize Therapeutics

Redwood City, US · Founded 2015 · Delaware corporation · 173 employees on LinkedIn · 13 known investors

Find your way into Galvanize Therapeutics

Sign up to see every warm intro you have to Galvanize Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Galvanize Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Galvanize Therapeutics develops surgical ablation technology using its proprietary Aliya Pulsed Electric Field (PEF) energy to destroy soft tissue cells through regulated cell death mechanisms. Its products serve clinical fields such as interventional pulmonology and thoracic surgery.

BiotechHealthtechMedical Devices

Founders & leadership

DGDoug Godshall
Doug GodshallChief Executive Officer
SASteve Anheier
Steve AnheierChief Financial OfficerPreviously, he was CFO at Vocera Communications (a publicly traded Bay Area company acquired by Stryker in 2022 for $3.1 billion) and held finance roles at Accuray Incorporated and KPMG, where he obtained his CPA.

Board

JW
Jonathan WaldstreicherBoard directorPartner at Apple Tree Venture Management Llc
APAntoine Papiernik
Antoine PapiernikBoard directorChairman and Managing Partner at Sofinnova Partners
SH
Seth HarrisonBoard director
ZSZack Scott
Zack ScottBoard directorGeneral Partner at Norwest Venture Partners
DLDavid Lewis
David LewisBoard directorFounder, Managing Partner at Gilmartin Capital LLC

Investors · 13

Ally Bridge GroupreportedNew York

How we know: funding news · prnewswire.com · Not right? Tell us

ATPreportedAustin

How we know: funding news · Not right? Tell us

Fidelity InvestmentsreportedBoston

How we know: funding news · prnewswire.com · Not right? Tell us

Gilmartin Capital LLCreportedLarkspur

How we know: funding news · prnewswire.com · Not right? Tell us

Janus Henderson InvestorsreportedLondon

How we know: prnewswire.com · Not right? Tell us

Perceptive Xontogeny VenturereportedNew York

How we know: funding news · prnewswire.com · Not right? Tell us

Sofinnova PartnersreportedParis · $540K – $27Mvia Antoine Papiernik · board

How we know: a partner's Signal profile · board seat on SEC Form D · funding news · prnewswire.com · Not right? Tell us

T. Rowe PricereportedBaltimore

How we know: prnewswire.com · Not right? Tell us

Also in the syndicate · 4

Apple Tree PartnersElevage Medical TechnologiesIntuitive SurgicalLongaeva

Reported raises · per SEC filings

Form D private placements

$150.7M disclosed across 5 rounds · 2015–2025

▶$96.1MraisedSep 2025 · 28 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Doug GodshallExecutive Officer, Director
  • Jonathan WaldstreicherExecutive Officer
  • Antoine PapiernikDirector
  • David LewisDirector
  • Steve AnheierExecutive Officer
  • Seth HarrisonDirector
  • Zack ScottDirector
Offering amount
$141.1M
Amount sold
$96.1M
First sale
Jul 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4MraisedMar 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jonathan WaldstreicherExecutive Officer, Director
  • Seth HarrisonDirector
  • Doug GodshallDirector
Offering amount
$4M
Amount sold
$4M
First sale
Mar 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedMar 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Seth HarrisonDirector
  • Doug GodshallDirector
  • Jonathan WaldstreicherExecutive Officer, Director
Offering amount
$2M
Amount sold
$2M
First sale
Feb 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.1MraisedOct 2020 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jonathan WaldstreicherExecutive Officer, Director
  • Seth HarrisonDirector
Offering amount
$16.1M
Amount sold
$6.1M
First sale
Mar 2020
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$42.5MraisedNov 2019 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jonathan WaldstreicherExecutive Officer, Director
  • Seth HarrisonDirector
Offering amount
$43M
Amount sold
$42.5M
First sale
Oct 2015
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
GalvanizeGalvanize provides customized technical education and training programs to help enterprise teams build skills in AI, machine learning, XP and Agile practices, data pipelines, and cloud operations. It focuses on onboarding, reskilling, upskilling, and assessments aimed at improving software delivery and business outcomes.
GalvanizeGalvanize Climate Solutions is an investment firm focused on the energy transition, deploying capital across areas such as climate risk analytics and clean energy. It publishes market perspectives on energy security, industrial policy, and competitiveness for investors.

Companies working in the same space as Galvanize Therapeutics.

In the news

Galvanize Therapeutics Raises $100M in Series C Financingfinsmes.com · Sep 2025Galvanize Therapeutics raises $100 million in Oversubscribed Series C Financing to Transform the Treatment of Cancer and Chronic Lung Diseaseprnewswire.com · Sep 2025

Frequently asked questions

What does Galvanize Therapeutics do?
Galvanize Therapeutics develops surgical ablation technology using its proprietary Aliya Pulsed Electric Field (PEF) energy to destroy soft tissue cells through regulated cell death mechanisms. Its products serve clinical fields such as interventional pulmonology and thoracic surgery.
Who are Galvanize Therapeutics's investors?
Galvanize Therapeutics's investors include Norwest Venture Partners, Ally Bridge Group, ATP, Fidelity Investments, Gilmartin Capital LLC, Janus Henderson Investors, Perceptive Xontogeny Venture, Sofinnova Partners and 1 more.
How much funding has Galvanize Therapeutics raised?
Galvanize Therapeutics has disclosed $150.7M raised across 5 rounds.
Where is Galvanize Therapeutics headquartered?
Galvanize Therapeutics is headquartered in Redwood City, US.